TD Study | C4C

The aim of this study is to explore the biology of tardive dyskinesia (TD), which is a disabling side effect of antipsychotic medication. It typically causes involuntary movements of the face, mouth, arms and legs. We will give valbenazine, a medication used to treat TD, to people with TD who also have schizophrenia or a mood disorder. We are looking to see whether valbenazine leads to any changes in brain functioning and whether these changes are linked to symptoms of TD. We will measure these changes using brain scans and clinical assessments before and during treatment with valbenazine. We hope to use CRIS to identify patients who may meet the criteria for our study.